InvestorsHub Logo
Followers 103
Posts 7202
Boards Moderated 0
Alias Born 03/29/2019

Re: Umibe5690 post# 237457

Friday, 07/26/2019 8:14:16 AM

Friday, July 26, 2019 8:14:16 AM

Post# of 704249
Umibe,

Again, thanks for a great post. I would like to comment briefly without quoting what your post says. That is because in order to clearly present what you are saying, I need to repeat your whole quote, which I don't want to do.

1. I need to wait for the published results on mPFS. It doesn’t make sense to me to have a vast improvement in mOS without a corresponding improvement in mPFS. If the GBM dynamics under DCVax-L is according to the model you suggested, then mOS should be the primary and possibly the only endpoint, imo. The team should have a dynamicist who should model the progression under DCVax-L administration. It is not essential, but at least that would be interesting to me.

2. I agree that the topline needs to be presented in a judicious manner. I believe that there are shareholders who are not going to benefit a great deal financially if the share price doesn’t increase significantly beyond the $1 to $2 range.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News